Skip to main content
ITHUF logo

ITHUF · iANTHUS CAPITAL HOLDINGS, INC.

Track ITHUF — free
$0.00 +0.00 (+2.44%) At close · Oct 20
Market Cap
$27.90M
Shares
6.97B
Volume · Oct 20 22.56K Avg daily vol (3M) 224.5K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.01 Avg vol 30d356K Short int9K · 0.0% float · 1.0d Short vol37% DataJan 2020–Oct 2026 Filing10-Q · Aug 12

Up next

filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$139.54M
Trailing 12 months
Net income (TTM)
−$55.37M
Trailing 12 months
Revenue growth YoY
+0.5%
Year over year
Operating margin
-9.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-80.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$195.27M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.2%
Year over year · more shares
Price change (1Y)
-47.5%
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −7%
below
Price vs 50-day avg −5%
below
RSI (14) 48
neutral
MACD trend Positive
52-week position 11%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −16%
trailing
YTD return −16%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -1.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 5-yr low, contrarian setup
Fundamentals
Weak
Revenue growth −14%
Y/Y
Gross margin 46%
expanding
Free cash flow $-20.6M
Balance sheet $182.1M
net debt
Quant / Vol
risk profile
Very High
Volatility 188%
annualized · 1-yr
Max drawdown −60%
past year
ATR 21.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−7% Bearish
Price vs 50-day avg
−5% Neutral
RSI (14)
48 Neutral
MACD trend
Positive Bullish
52-week position
11% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -1.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 5-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 11% Range high $0
vs 200-day avg -7% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $4.4M Q2 2026 —
EBITDA non-GAAP $1.49M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Net income (loss) -14.42M
+4.71M Depreciation and amortization
+4.17M Interest expense, net
+7.03M Income tax expense (benefit)
= EBITDA 1.49M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ITHUF
iANTHUS CAPITAL HOLDINGS, INC.
this stock
$27.90M -16.0% -14.1% — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
$64.15B +27.8% — — 0.1%
GALDY
Galderma Group AG
$48.88B +2.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$46.21B +30.2% +4.3% 65.0 2.6%
HLN
Haleon plc
$44.72B -0.9% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
Byrne Asset Management LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
8.5K
Days to cover
1.0d
Change
-118 sh
View
Short Volume
Short vol %
37%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
2.4K
Value
$0
As of
Apr 30, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$144.0M
Net income (FY)
$-40.2M
EPS diluted
$-0.01
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 12, 2026
This year
10
View
Exempt Offerings
Offering
$32.0M
Filed
Mar 18, 2020
View

Performance

5D 20D 120D MTD YTD
ITHUF -2.3% -8.7% -16.0% +10.5% -16.0%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -1.2% -8.1% -24.1% +9.7% -28.8%
Key facts CIK 1643154 CUSIP 45074T102 Visit website Investor relations